Together we can win more smiles

Targeted drug delivery (TDD)
allows your cancer patients 
to take control of their pain 
by giving them the ability to
manage breakthrough pain 
3 times faster compared to 
conventional medication 
and receive pain relief with 
less systemic opioid side effects.6,7,8

burden of cancer pain & side effects

HYPOTHESIS OF DISTRIBUTION OF PATIENTS BETWEEN THE WHO 3-STEP ANALGESIC LADDER IN REAL-LIFE PRACTICE (MODIFIED FROM ORHAN ET AL, 2008)4

hypothesis of distribution
hypothesis of distribution
hypothesis of distribution

PAIN RESPONSE TO TRANSDERMAL AND ORAL OPIOIDS - PATIENTS WITH MODERATE TO SEVERE PAIN mANAGEMENT ACCORDING TO STAGE 3 OF THE WHO ANALGESIC LADDER (MODIFIED FROM CORLI ET AL, 2016)5

Chart TDD

Adverse events related to transdermal and oral opioids – patients with moderate to severe pain managed according to stage 3 of the WHO analgesic ladder (Modified from Corli et al., 2016) 5

Chart TDD

MANAGE REFRACTORY CANCER PAIN WITH INTRAThECAL DRUG DELIVERY7,8,12

MORE PATIENTS with less fatigue and reduced consciousness compared to conventional medication.7

View Graph

MORE PATIENTS able to better control breakthrough pain and 3x faster with myPTM™ compared to conventional medication.6

View Graph

MORE PATIENTS with increased pain control and reduced toxicity compared to conventional medication.7

View Graph

WOULD I

DO IT AGAIN?

YES, BUT I WOULD DO IT EARLIER!

Sophie has benefited from TDD for refractory cancer pain for 2 years

* A communicator is needed between myPTM™ app / the clinician programmer and the pump for communication.

Patient selection recommendations

Patient Selection 1
Patient Selection 1
Patient Selection 1
Patient Selection 4

TOGETHER WE CAN WIN MORE SMILES

pdf Cancer Pain Implant Support Brochure (.pdf)

Intrathecal drug delivery for managing chronic cancer refractory pain

988KB

pdf Cancer Pain Referral Brochure (.pdf)

Intrathecal drug delivery for managing chronic cancer refractory pain

1012KB

pdf Cancer Pain Clinical Summary Stearns PSR FY20 (.pdf)

Intrathecal drug delivery systems for cancer pain: an analysis of a prospective, multicenter product surveillance registry. Anesthesia and Analgesia

159KB

pdf Cancer Pain Value Summary (.pdf)

Targeted drug delivery (TDD) allows your cancer patients to take control of their pain by giving them the ability to manage breakthrough pain 3 times faster compared to conventional medication

1.1MB

Brief Statement

See the device manual for detailed information regarding the Instructions For Use, the implant procedure, indications, contraindications, warnings, precautions and potential adverse events. For further information, contact your local Medtronic representative and/or consult the Medtronic website at www.medtronic.eu.

For applicable products, consult instructions for use on www.medtronic.com/manuals. Manuals can be viewed using a current version of any major Internet browser. For best results, use Adobe Acrobat Reader® with the browser. 

References

1

Ferlay J, Colombet M, Soerjomataram I, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries and 25 major cancers in 2018. Eur J Cancer. 2018 Nov;103:356-387.

2

Medtronic data on file. MarketScan Database. Accessed July 2015.

3

Breivik H, Cherny N, Collett B, et al. Cancer-related pain: a pan-European survey of prevalence, treatment, and patient attitudes. Annals of Oncology 2009;20(8): 1420-33.

4

Orhan ME, Bilgin F, Ergin A, et al. Pain treatment practice according to the WHO analgesic ladder in cancer patients: eight years experience of a single center. Agri. 2008;20(4):37–43.

5

Orhan ME, Bilgin F, Ergin A, et al. Pain treatment practice according to the WHO analgesic ladder in cancer patients: eight years experience of a single center. Agri. 2008;20(4):37–43.

6

Brogan E, Winter NB, Okifuji A. Prospective Observational Study of Patient-Controlled Intrathecal Analgesia: Impact on Cancer-Associated Symptoms, Breakthrough Pain Control, and Patient Satisfaction. Reg Anesth Pain Med. 2015;40(4):369–75.

7

Smith TJ, Staats PS, Deer T, et al. Randomized clinical trial of an implantable drug delivery (IDDS) system compared with comprehensive medical management (CMM) for refractory cancer pain: impact on pain, drug-related toxicity, and survival. J Clin Oncol. 2002;20(19):4040–9. 

8

Smith TJ, Coyne PJ. Implantable drug delivery systems (IDDS) after failure of comprehensive medical management (CMM) can palliate symptoms in the most refractory cancer pain patients. J Palliat Med. 2005;8(4):736–42.

9

Bhatia G, Lau ME, Koury KM, Gulur P. Intrathecal Drug Delivery (ITDD) systems for cancer pain. F1000Research 2014;2: 96-96.

10

Burton AW, Rajagopal A, Shah HN, et al. Epidural and intrathecal analgesia is effective in treating refractory cancer pain Pain Med. 2004 Sep;5(3):239-47.

11

Deer TR, Pope JE, Hayek SM, et al. The Polyanalgesic Consensus Conference (PACC): Recommendations on Intrathecal Drug Infusion Systems Best Practices and Guidelines. Neuromodulation. 2017;20(2):96–132.

12

Stearns L, Abd-Elsayed A, Perruchoud C, et. al. Intrathecal drug delivery systems for cancer pain: an analysis of a prospective, multicenter product surveillance registry. Anesthesia and Analgesia. 2019 Sep 18. doi: 10.1213/ANE.0000000000004425. [Epub ahead of print]